Braveheart Bio (NASDAQ:BRVE) Director Orbimed Advisors Llc Acquires 1,940,000 Shares of Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director Orbimed Advisors Llc bought 1,940,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $34,920,000.00. Following the completion of the acquisition, the director owned 11,901,826 shares of the company’s stock, valued at $214,232,868. This trade represents a 19.47% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Braveheart Bio Stock Performance

Shares of BRVE stock opened at $25.01 on Wednesday. Braveheart Bio, Inc. has a twelve month low of $24.61 and a twelve month high of $32.00.

Braveheart Bio Company Profile

We are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB?1893, is a next-generation oral small?molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non?obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.